基本信息
views: 189
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Born on 24/09/1965
H-Index: 65, Citations: 20933 (Google Scholar at 25/01/2022)
Number of publications in peer-review journals: 244 (including 11 reviews and 2 book chapters).
MAJOR RESEARCH INTERESTS
- Genetic predisposition to leukemia
- Personalized Medicine in Pediatric Hemato-Oncology
- Prenatal origin of leukemia and clonal evolution.
- Molecular characterization of childhood ALL and AML.
- Minimal residual disease monitoring in childhood ALL, by analysis of T-cell Receptor and Immunoglobulin genes’ rearrangements and fusion gene transcripts.
- Functional analysis of genetic aberrations in leukemic patients (PAX5 lesions, Ph-like ALL, Down Syndrome ALL, MLL-rearrangements).
- Leukemia Stem Cell
ORGANIZATIONAL / EDUCATIONAL / MANAGERIAL SKILLS
- Head of the Laboratory Tettamanti for Hemato-Oncological Diagnostics, coordinating 15 biologists and technicians working on cytomorphology and immunophenotyping, cytogenetics/molecular cytogenetics and molecular biology, for the diagnosis and monitoring of childhood and adult leukemia. The Laboratory if National reference for childhood ALL, and one of the main regional references for CML/MPD.
- Group Leader of the ‘Molecular Genetics of Leukemia’ Unit at the Tettamanti Research Center, coordinating a team of 3 PostDocs, 5 PhD students and 2 rotating ungraduated students.
- Founder and Board Member of the European Group for Minimal Residual Disease (EuroMRD, www.euromrd.org) analysis; Steering Committee member of the Euroclonality-NGS group, member of the Biology & Diagnosis Committee of the International-BFM Study Group (I-BFM-SG); board member of the Working Group on Biology of the Italian Association for Pediatric Hemato-Oncology (AIEOP); Management Committee member of the COST Action ‘Legend’ and vice-chair of WG3 on ‘Familial Leukemia’; Committee of the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza).
- Large experience in training and supervising students. Overall, 5 PhD students for the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza); 3 PhD students for the International PhD in Molecular Medicine (Università Vita-Salute San Raffaele, Milano); 2 students for their post-Degree Specialization in Medicine (Università Milano Bicocca, Monza); 13 students for their degree in Medicine (Università Milano Bicocca, Monza); 11 students for their degree in Biotechnology or Biology (Università Milano Bicocca, Monza and Università degli Studi, Milano); 3 students for their degree as Laboratory Technician (Università Milano Bicocca, Monza).
- Since 2011: yearly Teacher at the Master on Pediatric Hematology, Sapienza University, Rome, IT
COLLABORATIVE PROGRAMS
2018- JakNet - Italian network on Ph negative Myeloproliferative Disorders.
2016-now Campus ALL – Italian network on diagnosis, prognosis and treatment of ALL.
2015-now I-BFM Genetic Variation Task Force. Network on genetic predisposition to leukemia.
2013-now LabNet CML - Italian network on Cronic Myeloid Leukemia
2013-now EuroClonality-NGS Consortium on Next-Generation Sequencing for IG/TR immunogenetic analysis.
2008-now European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of RQ-PCR for BCR/ABL1 and ABL1 mutations.
2002-now European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of Clonality analysis and RQ-PCR for IG/TR.
2000-now MRD-Task Force: Report, Quality Control and Research Projects within the running childhood ALL therapeutic protocol in Italy, Germany, Austria (AIEOP-BFM ALL2000).
1999-now International-BFM Study Group. Biology and Diagnosis Committee.
1999-2002 Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program.
1995-1998 BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
- “Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease”.
- “Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets”.
REFEREES
− Reviewer of Nature Genetics, New England Journal of Medicine, Blood, Leukemia, Haematologica-The Hematology Journal, Leukemia Research, Leukemia and Lymphoma, Advances in Hematol, Ped Hematol Oncol, Ped Reports, Ped Blood and Cancer, and others.
− Reviewer of International Grant programs, member of the Scientific Committee of the Italian Association for Cancer Research (AIRC) for evaluation of Investigator Grants.
− Abstracts Reviewer for the American Society of Hematology, European Hematology Association and ESLHO meetings.
Research Interests
Papers共 534 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Heliyonno. 13 (2024): e34033
Blood (2024)
Molecular Cancerno. 1 (2024): 1-7
BLOOD ADVANCESno. 5 (2024): 1305-1319
Blood advancesno. 5 (2024): 1305-1319
Leukemiano. 6 (2023): 1216-1233
Laura Rachele Bettini, Rossana Sara Lauriola,Francesca Vendemini,Tiziana Coliva,Andrea Biondi,Giovanni Cazzaniga
Medico e bambinono. 4 (2023): 237-241
HemaSphereno. S3 (2023): e76470de-e76470de
American Journal of Hematologyno. 10 (2023)
CANCERSno. 14 (2023): 3624-3624
Load More
Author Statistics
#Papers: 541
#Citation: 21081
H-Index: 65
G-Index: 138
Sociability: 8
Diversity: 3
Activity: 88
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn